Literature DB >> 21799398

Peroperative effects of fresh frozen plasma and antithrombin III on heparin sensitivity and coagulation during nitroglycerine infusion in coronary artery bypass surgery.

Meral Kanbak1, Bahar Oc, Mehmet A Salman, Turgay Ocal, Mehmet Oc.   

Abstract

Nitroglycerin (NTG) reduces the anticoagulant effects of heparin and may lead to heparin resistance. Fresh frozen plasma (FFP) and antithrombin III (ATIII) may be used for the treatment of heparin resistance. We aimed to compare the effects of FFP and ATIII on heparin requirement, coagulation parameters, and bleeding in patients undergoing coronary artery bypass graft surgery (CABGS) with moderate dose of intraoperative NTG infusion. Forty-eight patients undergoing CABGS with NTG infusion were randomly allocated to three groups. Group C served as control, whereas the patients in group P received FFP and those in group A received ATIII after anesthesia induction. ATIII activity and coagulation parameters were measured at five different times intraoperatively. Total heparin requirement, heparin consumption, and heparin sensitivity were calculated. ATIII activity and ACT were significantly higher and activated partial thromboplastin time and fibrinogen level were significantly lower during cardiopulmonary bypass in group A than in groups P and C. Heparin sensitivity was significantly higher and total heparin requirement and consumption were significantly lower in ATIII group than in other groups. ATIII administration increases heparin sensitivity and decreases heparin requirements compared with FFP in patients undergoing CABGS with peroperative NTG infusion. ATIII may be preferred to FFP in patients with heparin resistance due to NTG infusion undergoing CABGS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21799398     DOI: 10.1097/MBC.0b013e32834a0478

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

1.  Supplementation with antithrombin III ex vivo optimizes enoxaparin responses in critically injured patients.

Authors:  Jessica C Cardenas; Yao-Wei Wang; Jay V Karri; Seenya Vincent; Andrew P Cap; Bryan A Cotton; Charles E Wade
Journal:  Thromb Res       Date:  2020-01-15       Impact factor: 3.944

2.  Antithrombin concentrate use in children: a multicenter cohort study.

Authors:  Trisha E Wong; Yuan-Shung Huang; Jason Weiser; Thomas V Brogan; Samir S Shah; Char M Witmer
Journal:  J Pediatr       Date:  2013-08-06       Impact factor: 4.406

Review 3.  Antithrombin III for critically ill patients.

Authors:  Mikkel Allingstrup; Jørn Wetterslev; Frederikke B Ravn; Ann Merete Møller; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2016-02-08

Review 4.  Fresh frozen plasma for cardiovascular surgery.

Authors:  Michael Desborough; Ravinda Sandu; Susan J Brunskill; Carolyn Doree; Marialena Trivella; Alessandro Montedori; Iosief Abraha; Simon Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

5.  Preoperative Low-Molecular-Weight Heparin Prophylaxis Associated with Increased Heparin Resistance Frequency in On-Pump Coronary Artery Bypass Graft Surgery.

Authors:  Onur Saydam; Mehmet Atay; Deniz Serefli; Suat Doganci; Ulas Kumabasar; Mustafa Yılmaz; Rıza Dogan; Metin Demircin
Journal:  Cardiol Res Pract       Date:  2019-04-16       Impact factor: 1.866

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.